When a one-day gain of 20% or more becomes a signal of action
On July 21, 2025, investors witnessed a rare session on the NASDAQ as shares of several companies soared higher, beating analysts’ expectations and creating waves of discussion on Reddit, Twitter, and in professional circles. Opendoor Technologies, ProMIS Neurosciences, ZimVie, and Offerpad are among the leaders. Let’s find out what’s behind their rapid growth, what the market reaction is, and what to expect next.
Opendoor Technologies (NASDAQ: OPEN) +59% for the day
From delisting candidate to speculator favorite
Shares of Opendoor, a digital platform for real estate transactions, saw a sharp jump after a comment from EMJ Capital CEO Eric Jackson, who said the company “could very well become a 100-bagger,” meaning it could show a hundred-fold increase in value. Despite the hyperbole in the valuation, attention to OPEN increased manifold. This triggered a wave of activity among retail traders, especially against the backdrop of the recent reverse split, which reduced the risk of delisting.
Factors that influenced the growth:
- Reverse split of the stock, which reduced the total number of securities and improved the perception in the market
- Improved macro conditions in the housing market due to lower mortgage rates
- Active discussion on Reddit and trader forums
Investment Outlook. Despite the impressive jump, Opendoor remains a high-risk story. However, with continued positive momentum in the real estate sector and rate stability, the $2.5-3 level could be a target zone. For long-term investors, it is critical to keep an eye on quarterly reports and market reaction.
Opendoor Technologies: Explosive growth or temporary fever?
ProMIS Neurosciences (NASDAQ: PMN) +135% on a breakthrough in biotechnology
New front in the fight against Alzheimer’s disease
A Canadian biotech company stunned the market with preliminary data on a drug that can slow neurodegenerative processes, including Alzheimer’s disease. No surprise, as the topic of aging populations and dementia is an increasingly hot topic on a global scale.
Why the market reacted:
- Encouraging results from preclinical and early phase studies
- Potential interest from large pharma companies such as Biogen and Eli Lilly
Analytics. If the next phases of clinical trials confirm efficacy, ProMIS could be the target of a strategic partnership or buyout. For investors, a chance to get in on a long-term story early on, but with high volatility and regulatory risks.
ZimVie Inc. (NASDAQ: ZIMV) +122% after a strong report
Medical devices are returning to investor focus
ZimVie, a manufacturer of implants and equipment for neurosurgery, surprised analysts with unexpectedly strong second quarter results. A sharp improvement in operating margins and a lower debt load bolstered institutional investor confidence.
Key growth triggers:
- Revenue growth on the back of cost reductions
- Improved cash flow and restructuring of the manufacturing base
- Increased interest in medical technology in the face of an aging population
Outlook. If the positive momentum continues, ZIMV stock could cross the $7 threshold and continue to move higher. Investors should keep a close eye on reporting and potential product line expansion initiatives.
Offerpad Solutions (NASDAQ: OPAD) +45.6% and a rebound in the iBuying segment
A quiet player that’s back in the game
Offerpad, like Opendoor, operates in the iBuying segment – the rapid digital buying and selling of real estate. The latest reporting showed a 12% quarter-on-quarter revenue growth, lower operating losses and hints of a strategic partner coming on board, triggering a wave of acquisitions.
Why the market reacted:
- Revenue growth as the housing market stabilized
- Rising debt coverage ratios
- Active participation of venture capitalists and rumors of consolidation
Conclusion. Pullbacks are possible in the short term, but if positive trends continue, OPAD could show a recovery to 2023-2024 levels. For speculators this is a field for quick trades, for strategists it is a reason to keep an eye on diversification of the company’s business.
| Company | Daily Gain | Growth Catalyst |
|---|
| Opendoor | +59% | Reddit buzz, reverse split, housing market |
| ProMIS | +135% | Breakthrough in Alzheimer’s treatment |
| ZimVie | +122% | Strong earnings report, operational efficiency |
| Offerpad | +45.6% | Revenue growth, strategic partnership rumors |
What an investor should do
Strategy for active traders
Sharp movements in one trading session attract the attention of short-term traders. However, it is important to remember that such dynamics is associated with high volatility. Against the background of strong movements, it is necessary to strictly observe risk management, use stop-losses and determine the exit level in advance.
Prospects for a long-term approach
Of the companies presented, ProMIS – due to its unique niche and potential in biopharma – and ZimVie, which is showing signs of sustained growth and improving metrics, may be of particular interest. Both companies deserve a place on the watch list of a growth-oriented investor with a 12-24 month horizon.
Financial Outlook
One-day growth above 20% is not just a number, but an indicator of market attention. There is either a fundamental shift or speculative interest behind it. Either way, an investor’s reaction should be calibrated: studying reports, assessing the industry, analyzing the behavior of major players. This helps distinguish short-term noise from a real signal to action.
For those who are looking for quality dividend stocks, we have prepared a selection “The best dividend stocks of 2025: where reliable income meets high demand” – an ideal benchmark for forming a balanced portfolio with an eye on stable returns.
For those who follow companies in Latin America and prefer long-term stories with a strong cash position, we recommend the article “Aris Mining (ARMN): Cash-Rich, Focused, and Gaining Momentum in Latin America”. The article provides a comprehensive look at the company’s strategy and an assessment of its future growth drivers.
We also recommend you to take a look at the analytical review “CRISPR and biotech equity investments as a new growth vector”, as biotechnology remains one of the key areas for investors in US equities.
